Literature DB >> 21831443

Poxvirus A46 protein binds to TIR domain-containing Mal/TIRAP via an α-helical sub-domain.

Shun-Ichiro Oda1, Edward Franklin, Amir R Khan.   

Abstract

Poxviruses are large DNA viruses that replicate in the cytosol and express numerous proteins to subvert the host immunity. Vaccinia virus A46 is a 25kDa protein that antagonizes multiple components of the Toll-like/interleukin-1 receptor (TLR) pathway by targeting cytosolic adaptor proteins. A46 binds to MyD88, Mal/TIRAP, TRIF and TRAM and suppresses the activation of NF-κB and interferon regulatory factors. Each of these cytosolic adaptors has a TIR domain that is critical for oligomerization during signaling. Although the structure of A46 is unknown, it has alternatively been described as an α/β-fold TIR domain, or an all α-helical Bcl-2 fold. Here we provide experimental evidence that the C-terminus of A46 adopts a dimeric α-helical structure, and that this segment retains the ability to interact with monomeric Mal. Furthermore, a peptide fragment of A46 termed VIPER, previously shown to retain the biological properties of the full-length protein, does not interact with Mal in vitro. In summary, we provide for the first time a biophysical analysis of the binding of a poxvirus protein to a TIR domain-containing adaptor molecule.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21831443     DOI: 10.1016/j.molimm.2011.07.014

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  8 in total

1.  Poxviral protein A46 antagonizes Toll-like receptor 4 signaling by targeting BB loop motifs in Toll-IL-1 receptor adaptor proteins to disrupt receptor:adaptor interactions.

Authors:  Julianne Stack; Andrew G Bowie
Journal:  J Biol Chem       Date:  2012-05-16       Impact factor: 5.157

2.  Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.

Authors:  Juan García-Arriaza; Carmen E Gómez; Carlos Óscar S Sorzano; Mariano Esteban
Journal:  J Virol       Date:  2014-01-03       Impact factor: 5.103

3.  A Decoy Peptide that Disrupts TIRAP Recruitment to TLRs Is Protective in a Murine Model of Influenza.

Authors:  Wenji Piao; Kari Ann Shirey; Lisa W Ru; Wendy Lai; Henryk Szmacinski; Greg A Snyder; Eric J Sundberg; Joseph R Lakowicz; Stefanie N Vogel; Vladimir Y Toshchakov
Journal:  Cell Rep       Date:  2015-06-18       Impact factor: 9.423

4.  Structure of vaccinia virus A46, an inhibitor of TLR4 signaling pathway, shows the conformation of VIPER motif.

Authors:  Yongwoon Kim; Hasup Lee; Lim Heo; Chaok Seok; Jungwoo Choe
Journal:  Protein Sci       Date:  2014-04-28       Impact factor: 6.725

5.  Characterization and structure of the vaccinia virus NF-κB antagonist A46.

Authors:  Sofiya Fedosyuk; Irina Grishkovskaya; Euripedes de Almeida Ribeiro; Tim Skern
Journal:  J Biol Chem       Date:  2013-12-19       Impact factor: 5.157

6.  Toll-like receptor 4 inhibition within the paraventricular nucleus attenuates blood pressure and inflammatory response in a genetic model of hypertension.

Authors:  Rahul B Dange; Deepmala Agarwal; Ryoichi Teruyama; Joseph Francis
Journal:  J Neuroinflammation       Date:  2015-02-18       Impact factor: 8.322

Review 7.  Paradoxical Roles of the MAL/Tirap Adaptor in Pathologies.

Authors:  Imène Belhaouane; Eik Hoffmann; Mathias Chamaillard; Priscille Brodin; Arnaud Machelart
Journal:  Front Immunol       Date:  2020-09-25       Impact factor: 7.561

8.  Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C.

Authors:  Beatriz Perdiguero; Carmen Elena Gómez; Mauro Di Pilato; Carlos Oscar S Sorzano; Julie Delaloye; Thierry Roger; Thierry Calandra; Giuseppe Pantaleo; Mariano Esteban
Journal:  PLoS One       Date:  2013-09-17       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.